
NYSE:GMED
This summary was created by AI, based on 1 opinions in the last 12 months.
The current sentiment surrounding Globus Medical (GMED-N) reflects a broader bearish trend in the medical device industry, with market experts noting a significant aversion towards stocks in this sector. The challenges faced by major players like Medtronic indicate a tougher financial landscape for medical device companies, including Globus Medical, as investors express concerns over growth and profitability. The outlook suggests that there may be limited opportunities for substantial gains in the near term, which could weigh heavily on the company's stock performance. Given these factors, cautious evaluation is warranted for potential investors, as the overall market climate seems unfavorable for medical device firms at this time.
He recommended it around 18 months ago, and it has doubled in price. Drawbacks before: had no international presence and not enough salespeople, but that has turned around, as reflected in the price jump. Earnings growing 10-15% annually. No debt, but pay no dividend. Buy half a position and watch, but don't buy heavily because it may
drop badly during a correction.
Since he recommended this, it’s gone from $22 to $46. This is medical technology for spying related injuries. The stock price has taken off because the company has gotten their act together and has started to move outside of the US. Their sales teams are in place. A lot of their competitors have not been allocating capital towards the spine business. This company just came out with a new robotic invention that will help surgeons do all the spine surgeries. Earnings have jumped up nicely, and he is expecting anywhere from $143-$178 a share over the next couple of years, but we are still seeing the stock trading at roughly 32X earnings. Wait for a pullback or just buy half for the moment.
Globus Medical is a American stock, trading under the symbol GMED (previously GMED-N on Stockchase) on the New York Stock Exchange (GMED). It is usually referred to as NYSE:GMED or GMED
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on GMED (previously GMED-N on Stockchase). 0 analysts recommended to BUY and 1 analyst recommended to SELL the stock. The latest stock analyst rating is DON'T BUY. Read the latest stock experts' ratings for Globus Medical.
Globus Medical was recommended as a Top Pick by Jim Cramer - Mad Money on 2026-05-15. Read the latest stock experts ratings for Globus Medical.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Globus Medical.
Globus Medical is followed by 10 investors on Stockchase and is a trending stock that is worth watching.
On 2026-07-23, Globus Medical (GMED) stock closed at a price of $75.42.
The market hates medical devices now and there's little money made in bigger players like Medtronic.